

Abemaciclib

Section	Indications
Targeted therapies	Therapeutic equivalent to palbociclib for Other specified malignant neoplasms of breast

Afatinib

Section	Indications
Targeted therapies	Therapeutic equivalent to erlotinib for Other specified malignant neoplasms of bronchus or lung

All-trans retinoic acid

Section	Indications
Targeted therapies Oral > Solid: 10 mg capsule	Acute myeloid leukaemia with recurrent genetic abnormalities

Binimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib for Other specified melanoma of skin

Bortezomib

Section	Indications
Targeted therapies Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection	Plasma cell myeloma

Cobimetinib

Section	Indications
Targeted therapies	Therapeutic equivalent to trametinib for Other specified melanoma of skin

Crizotinib

Section

Targeted therapies

Oral > Solid: 200 mg; 250 mg

Oral > Solid > capsule: 200 mg; 250 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Anaplastic large cell lymphoma, ALK-positive

Dabrafenib

Section

Targeted therapies

Oral > Solid: 50 mg; 75 mg

Indications

Other specified melanoma of skin

Dasatinib

Section

Targeted therapies

Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

Chronic myeloid leukaemia, not elsewhere classified

Encorafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

Erlotinib

Section

Targeted therapies

Oral > Solid: 100 mg; 150 mg

Indications

Other specified malignant neoplasms of bronchus or lung

Everolimus

Section

Targeted therapies

Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)

Indications

Other specified gliomas of brain

Gefitinib

Section

Targeted therapies

Indications

Therapeutic equivalent to erlotinib for

Other specified malignant neoplasms of bronchus or lung

Ibrutinib

Section

Targeted therapies

Oral > Solid: 140 mg

Indications

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Imatinib

Section

Targeted therapies

Oral > Solid: 100 mg; 400 mg

Indications

B lymphoblastic leukaemia or lymphoma with t(9:22) (q34;q11.2); BCR-ABL1

Gastrointestinal stromal tumour of unspecified gastrointestinal sites

Chronic myeloid leukaemia, not elsewhere classified

Nilotinib

Section

Targeted therapies

Oral > Solid: 150 mg capsule; 200 mg capsule

Indications

Chronic myeloid leukaemia, not elsewhere classified

Osimertinib

Section

Targeted therapies

Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

Other specified malignant neoplasms of bronchus or lung

Palbociclib

Section

Targeted therapies

Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

Other specified malignant neoplasms of breast

Pertuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

Indications

Carcinoma of breast, specialised type

Ribociclib

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) for

Other specified malignant neoplasms of breast

Rituximab

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

Follicular lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

Trametinib

Section

Targeted therapies

Oral > Solid: 0.5 mg; 2 mg

Indications

Other specified melanoma of skin

Trastuzumab

Section

Targeted therapies

Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Trastuzumab emtansine

Section

Targeted therapies

Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

Carcinoma of breast, specialised type

Vemurafenib

Section

Targeted therapies

Indications

Therapeutic equivalent to dabrafenib for

Other specified melanoma of skin

Zanubrutinib

Section

Targeted therapies

Oral > Solid: 80 mg

Indications

Mantle cell lymphoma

Chronic lymphocytic leukaemia or small lymphocytic lymphoma